Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.41 |
| ▸ | GSR | P00390 | 2/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8234920 | 0.83 | NOS3 (0.46) | SLC1A5SLC1A1GRIK1SLC1A3SLC1A2 | |
| SCHEMBL21531603 | 0.83 | NOS3 (0.46) | SLC1A5SLC1A1GRIK1SLC1A3SLC1A2 | |
| SCHEMBL21973559 | 0.82 | SLC1A1 (0.44) | SLC1A5SLC1A1GSRGRIK1GRIK2 | |
| SCHEMBL7991509 | 0.81 | GRM8 (0.50) | SLC1A5SLC1A1GSRGRIK1GRIK2 | |
| Glycine SCHEMBL8588130 | 0.81 | GLRA1 (0.42) | SLC1A5SLC1A1GSRGRIK1GRIK2 | |
| SCHEMBL4893526 | 0.80 | SLC1A5 (0.43) | SLC1A5SLC1A1GSRGRIK1GRIK2 | |
| SCHEMBL352049 | 0.80 | SLC1A5 (0.43) | SLC1A5SLC1A1GSRGRIK1GRIK2 | |
| SCHEMBL4893529 | 0.80 | SLC1A5 (0.43) | SLC1A5SLC1A1GSRGRIK1GRIK2 | |
| SCHEMBL3502798 | 0.80 | SLC1A5 (0.43) | SLC1A5SLC1A1GSRGRIK1GRIK2 | |
| SCHEMBL21531606 | 0.79 | SLC1A1 (0.48) | SLC1A1GSRGRIK1GRIK2GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562950-B1 | PROCESS FOR THE SYNTHESIS OF FUNCTIONALIZED CYCLIC DITHIOCARBAMATES | ARKEMA FRANCE (FR) | 2024-10-02 | — | — | EP | claimed |
| CN-110100004-B | Synthesis of functionalized cyclic dithiocarbamic acid or ester | 阿肯马法国公司 | 2023-09-19 | — | — | CN | claimed |
| US-20230159967-A1 | FUNCTIONALISED POLSULPHIDE SYNTHESIS METHOD | ARKEMA FRANCE (FR) | 2023-05-25 | — | — | US | claimed |
| US-11643673-B2 | Functionalised cyclic dithiocarbamate synthesis method | ARKEMA FRANCE (FR) | 2023-05-09 | — | — | US | claimed |
| US-20200149080-A1 | FUNCTIONALISED CYCLIC DITHIOCARBAMATE SYNTHESIS METHOD | ARKEMA FRANCE (FR) | 2020-05-14 | — | — | US | claimed |
| US-20190338325-A1 | FUNCTIONALISED POLYSULPHIDE SYNTHESIS METHOD | ARKEMA FRANCE (FR) | 2019-11-07 | — | — | US | claimed |
| EP-3562950-B1 | PROCESS FOR THE SYNTHESIS OF FUNCTIONALIZED CYCLIC DITHIOCARBAMATES | ARKEMA FRANCE (FR) | 2024-10-02 | — | — | EP | disclosed |
| US-20240002893-A1 | PROCESS FOR SYNTHESIZING FUNCTIONALIZED MERCAPTANS UNDER AN H2S PRESSURE | ARKEMA FRANCE (FR) | 2024-01-04 | — | — | US | disclosed |
| EP-4255887-A1 | METHOD FOR SYNTHESISING FUNCTIONALISED MERCAPTANS UNDER H2S PRESSURE | ARKEMA FRANCE (FR) | 2023-10-11 | — | — | EP | disclosed |
| US-20230295080-A1 | IMPROVED PROCESS FOR SYNTHESIZING FUNCTIONALIZED MERCAPTANS | ARKEMA FRANCE (FR) | 2023-09-21 | — | — | US | disclosed |
| CN-110100004-B | Synthesis of functionalized cyclic dithiocarbamic acid or ester | 阿肯马法国公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116601143-A | For at H 2 Method for synthesizing functionalized mercaptan under S pressure | 阿科玛法国公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230159967-A1 | FUNCTIONALISED POLSULPHIDE SYNTHESIS METHOD | ARKEMA FRANCE (FR) | 2023-05-25 | — | — | US | disclosed |
| EP-4182300-A1 | IMPROVED METHOD FOR SYNTHESISING FUNCTIONALISED MERCAPTANS | ARKEMA FRANCE (FR) | 2023-05-24 | — | — | EP | disclosed |
| US-11643673-B2 | Functionalised cyclic dithiocarbamate synthesis method | ARKEMA FRANCE (FR) | 2023-05-09 | — | — | US | disclosed |
| US-11578345-B2 | Functionalised polysulphide synthesis method | ARKEMA FRANCE (FR) | 2023-02-14 | — | — | US | disclosed |
| WO-2022117951-A1 | METHOD FOR SYNTHESISING FUNCTIONALISED MERCAPTANS UNDER H2S PRESSURE | ARKEMA FRANCE (FR) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578345-B2 | Functionalised polysulphide synthesis method | STS, PFAS, SCLY | SLC1A5 3268/4885SLC1A1 3786/4885GSR 412/4885 |
| US-11643673-B2 | Functionalised cyclic dithiocarbamate synthesis method | TST, DTYMK, DDO | SLC1A5 3093/4885SLC1A1 3113/4885GSR 633/4885 |
| US-20190338325-A1 | FUNCTIONALISED POLYSULPHIDE SYNTHESIS METHOD | STS, PFAS, SCLY | SLC1A5 3268/4885SLC1A1 3786/4885GSR 412/4885 |
| US-20200149080-A1 | FUNCTIONALISED CYCLIC DITHIOCARBAMATE SYNTHESIS METHOD | TST, DTYMK, DDO | SLC1A5 3093/4885SLC1A1 3113/4885GSR 633/4885 |
| US-20230159967-A1 | FUNCTIONALISED POLSULPHIDE SYNTHESIS METHOD | POLH, POLD1, POLR2H | SLC1A5 4417/4885SLC1A1 4190/4885GSR 1179/4885 |
| US-20230295080-A1 | IMPROVED PROCESS FOR SYNTHESIZING FUNCTIONALIZED MERCAPTANS | CBR3, RTN3, OR10J3 | SLC1A5 1066/4885SLC1A1 1643/4885GSR 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.